L.L. Miller

1.1k total citations
30 papers, 900 citations indexed

About

L.L. Miller is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, L.L. Miller has authored 30 papers receiving a total of 900 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Molecular Biology, 15 papers in Oncology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in L.L. Miller's work include Muscle Physiology and Disorders (8 papers), Neutropenia and Cancer Infections (7 papers) and Cancer therapeutics and mechanisms (6 papers). L.L. Miller is often cited by papers focused on Muscle Physiology and Disorders (8 papers), Neutropenia and Cancer Infections (7 papers) and Cancer therapeutics and mechanisms (6 papers). L.L. Miller collaborates with scholars based in United States, United Kingdom and Israel. L.L. Miller's co-authors include Gary Elfring, R P Mischak, Archie Khentigan, Nancy Wedel, Maguy Del Rio, N A Brophy, W. Scott Harkonen, Lynn E. S̄pitler, William H. Sharfman and Kevin C. Conlon and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer Research.

In The Last Decade

L.L. Miller

28 papers receiving 867 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
L.L. Miller United States	13	335	332	229	220	141	30	900
Daisuke Ito Japan	14	573 1.7×	291 0.9×	107 0.5×	135 0.6×	119 0.8×	48	1.2k
Sarah H. Tannehill‐Gregg United States	16	338 1.0×	301 0.9×	248 1.1×	47 0.2×	80 0.6×	24	782
Roger Coleman United States	15	498 1.5×	271 0.8×	306 1.3×	85 0.4×	149 1.1×	44	1.0k
L. M. Ellis United States	12	585 1.7×	371 1.1×	225 1.0×	67 0.3×	83 0.6×	20	1.1k
Aleck Hercbergs United States	21	379 1.1×	280 0.8×	107 0.5×	84 0.4×	121 0.9×	40	1.1k
Amer M. Mirza United States	16	572 1.7×	316 1.0×	184 0.8×	334 1.5×	54 0.4×	32	1.3k
Oliver J. Stoetzer Germany	14	256 0.8×	206 0.6×	97 0.4×	97 0.4×	59 0.4×	29	625
Frank Revetta United States	18	473 1.4×	516 1.6×	147 0.6×	175 0.8×	132 0.9×	40	1.2k
Wim H.A. Dokter Netherlands	19	471 1.4×	572 1.7×	75 0.3×	252 1.1×	128 0.9×	44	1.3k
Valentina Rossi Italy	15	397 1.2×	239 0.7×	135 0.6×	63 0.3×	107 0.8×	26	773

Countries citing papers authored by L.L. Miller

Since Specialization

Citations

This map shows the geographic impact of L.L. Miller's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by L.L. Miller with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites L.L. Miller more than expected).

Fields of papers citing papers by L.L. Miller

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by L.L. Miller. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by L.L. Miller. The network helps show where L.L. Miller may publish in the future.

Co-authorship network of co-authors of L.L. Miller

This figure shows the co-authorship network connecting the top 25 collaborators of L.L. Miller. A scholar is included among the top collaborators of L.L. Miller based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with L.L. Miller. L.L. Miller is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Konecny, Gottfried E., Andrea Wahner Hendrickson, Boris Winterhoff, et al.. (2024). PR031/#1199 Phase I, two-part, mutlicenter, first-in-human (FIH) study of TORL-1–23, a novel claudin 6 (CLDN6) targeting antibody drug conjugate (ADC) in patients with advanced solid tumors. A56.1–A56.

Wilschanski, Michael, L.L. Miller, David Shoseyov, et al.. (2011). Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis. European Respiratory Journal. 38(1). 59–69. 151 indexed citations

Finkel, Richard S., Brenda Wong, K. Bushby, et al.. (2010). P3.51 Results of a Phase 2b, dose-ranging study of ataluren (PTC124®) in nonsense mutation Duchenne/Becker muscular dystrophy (nmDBMD). Neuromuscular Disorders. 20(9-10). 656–657. 12 indexed citations

McDonald, Craig M., Erik Henricson, Richard T. Abresch, et al.. (2009). M.P.3.03 6-minute walk test in Duchenne muscular dystrophy: Longitudinalobservations. Neuromuscular Disorders. 19(8-9). 601–602. 2 indexed citations

Florence, Julaine, Richard T. Abresch, Michelle Eagle, et al.. (2009). T.P.3.05 Reproducibility and correlation of pretreatment outcome measures in phase 2b study of ataluren (PTC124™) in nonsense mutation Duchenne and Becker muscular dystrophy (nmDMD/BMD). Neuromuscular Disorders. 19(8-9). 611–612. 2 indexed citations

Tiersten, Amy, Harry Miao, Gary Elfring, et al.. (2009). PTC299, a Novel Regulator of Tumor VEGF Expression, Is Well Tolerated and Achieves Target Plasma Concentrations: Dose-Ranging Results of a Phase 1b Study in Women with Metastatic Breast Cancer.. Cancer Research. 69(24_Supplement). 6092–6092. 4 indexed citations

McDonald, Craig M., Kim Coleman, Erik Henricson, et al.. (2009). M.P.3.04 Assessment of StepWatch™ activity monitoring in phase 2b study of ataluren (PTC124™) in nmDMD/BMD. Neuromuscular Disorders. 19(8-9). 602–602. 5 indexed citations

Abresch, Richard T., Julaine Florence, Eduard Gappmaier, et al.. (2009). M.P.3.05 Use of a novel system for grading timed function test performance in phase 2b study of ataluren (PTC124™) in nonsense mutation Duchenne and Becker muscular dystrophy (nmDMD/BMD). Neuromuscular Disorders. 19(8-9). 602–602. 2 indexed citations

Reha, A., Gary Elfring, Richard S. Finkel, et al.. (2008). T.P.5.01 Phase 2b Study of PTC124 in Duchenne/Becker muscular dystrophy (DMD/BMD): Demographic and other baseline data. Neuromuscular Disorders. 18(9-10). 823–823. 5 indexed citations

10.

Wilschanski, M., S. Armoni, Yasmin Yaakov, et al.. (2008). PTC124 treatment over 3 months improves pharmacodynamic and clinical parameters in patients with nonsense-mutation-mediated CF. Journal of Cystic Fibrosis. 7. S22–S22. 10 indexed citations

11.

Finkel, Richard S., Brenda Wong, Kevin M. Flanigan, et al.. (2007). G.P.3.05 Phase 2 study of PTC124 for nonsense mutation suppression therapy of Duchenne muscular dystrophy (DMD). Neuromuscular Disorders. 17(9-10). 783–783. 7 indexed citations

12.

Hirawat, Samit, Steven Ramael, Valerie Northcutt, et al.. (2006). 51 POSTER Phase 1 single-dose safety, PK, and food-effect study of PTC299, a novel VEGF expression inhibitor for treatment of solid tumors. European Journal of Cancer Supplements. 4(12). 19–20.

13.

Goldberg, Richard M., Scott H. Kaufmann, Pamela J. Atherton, et al.. (2002). A phase I study of sequential irinotecan and5-fluorouracil/leucovorin. Annals of Oncology. 13(10). 1674–1680. 11 indexed citations

14.

Rothenberg, Mace L., John G. Kuhn, Larry J. Schaaf, et al.. (2001). Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks. Annals of Oncology. 12(11). 1631–1641. 32 indexed citations

15.

Blanke, Charles D., Daniel G. Haller, Al B. Benson, et al.. (2001). A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinoma. Annals of Oncology. 12(11). 1575–1580. 48 indexed citations

16.

Saltz, Leonard B., David R. Spriggs, Larry J. Schaaf, et al.. (1998). Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors.. Journal of Clinical Oncology. 16(12). 3858–3865. 48 indexed citations

17.

Janik, John E., L.L. Miller, Daniele Longo, et al.. (1996). Phase II Trial of Interleukin 1 and Indomethacin in Treatment of Metastatic Melanoma. JNCI Journal of the National Cancer Institute. 88(1). 44–49. 22 indexed citations

18.

Arbuck, Susan G., et al.. (1996). Phase I trial of etoposide, doxorubicin and cisplatin (EAP) in combination with GM-CSF. European Journal of Cancer. 32(4). 631–635. 4 indexed citations

19.

O’Dwyer, Peter J., Russell J. Schilder, C McAleer, et al.. (1992). Phase I trial of thiotepa in combination with recombinant human granulocyte-macrophage colony-stimulating factor.. Journal of Clinical Oncology. 10(8). 1352–1358. 21 indexed citations

20.

Smith, John W., Walter J. Urba, Brendan D. Curti, et al.. (1992). The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignancies.. Journal of Clinical Oncology. 10(7). 1141–1152. 136 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact